Advertisement
Journal of Investigative Dermatology Home

Efficacy and Safety of Tacrolimus 0.1% for the Treatment of Facial Vitiligo: A Multicenter Randomized, Double-Blinded, Vehicle-Controlled Study

Published:February 04, 2021DOI:https://doi.org/10.1016/j.jid.2020.12.028

      Background

      Topical calcineurin inhibitors are used off label in the treatment of vitiligo, and there is a lack of placebo-controlled, blinded studies to support their use.

      Objective

      This study aimed to compare the efficacy of tacrolimus 0.1% ointment with that of the vehicle for repigmentation in adult patients with facial vitiligo.

      Design

      This study was a 24-week multicenter randomized parallel double-blind study with a 24-week post-treatment follow-up extension.

      Population

      Participants included were adult patients with recent facial vitiligo target lesions (<2 years) without changes in pigmentation or size over the previous 3 months.

      Intervention

      Patients received either tacrolimus 0.1% ointment or vehicle twice daily.

      Main Outcomes and Measures

      The primary outcome was a therapeutic success, defined as a change ≥75% in the repigmentation of the target lesion between baseline and week 24, measured by ImageJ software. Secondary outcome measures were a variation of the physicians’ global assessment scores and patients’ satisfaction scores, safety data, and the rate of relapse at week 48.

      Results

      A total of 42 patients were included. Therapeutic success was achieved in 65% of tacrolimus-treated patients versus 0% of vehicle-treated patients at week 24 (P < 0.0001). Only 40% of relapse was observed at 48 weeks.

      Conclusions and Relevance

      Twice-daily tacrolimus 0.1% ointment showed superior efficacy to that of the vehicle through the 24 weeks of intervention and 24 weeks of follow-up in adult patients with facial vitiligo.

      Trial Registration

      This study was registered at ClinicalTrials.gov (identifier: NCT02466997).

      Abbreviations:

      DLQI (Dermatology Quality of Life Index), TCI (topical calcineurin inhibitor), VIPs (Vitiligo Impact Patient scale)
      To read this article in full you will need to make a payment
      Purchase one-time access
      Society Members (SID/ESDR), remember to log in for access.
      Subscribe to Journal of Investigative Dermatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Boniface K.
        • Jacquemin C.
        • Darrigade A.S.
        • Dessarthe B.
        • Martins C.
        • Boukhedouni N.
        • et al.
        Vitiligo skin is imprinted with resident memory CD8 T cells expressing CXCR3.
        J Invest Dermatol. 2018; 138: 355-364
        • Boniface K.
        • Seneschal J.
        Vitiligo as a skin memory disease: the need for early intervention with immunomodulating agents and a maintenance therapy to target resident memory T cells.
        Exp Dermatol. 2019; 28: 656-661
        • Boniface K.
        • Seneschal J.
        • Picardo M.
        • Taïeb A.
        Vitiligo: focus on clinical aspects, immunopathogenesis, and therapy.
        Clin Rev Allergy Immunol. 2018; 54: 52-67
        • Cavalié M.
        • Ezzedine K.
        • Fontas E.
        • Montaudié H.
        • Castela E.
        • Bahadoran P.
        • et al.
        Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebo–controlled study.
        J Invest Dermatol. 2015; 135: 970-974
        • Cheuk S.
        • Schlums H.
        • Gallais Sérézal I.
        • Martini E.
        • Chiang S.C.
        • Marquardt N.
        • et al.
        CD49a expression defines tissue-resident CD8+ T cells poised for cytotoxic function in human skin.
        Immunity. 2017; 46: 287-300
        • Elbuluk N.
        • Ezzedine K.
        Quality of life, burden of disease, co-morbidities, and systemic effects in vitiligo patients.
        Dermatol Clin. 2017; 35: 117-128
        • Eleftheriadou V.
        • Hamzavi I.
        • Pandya A.G.
        • Grimes P.
        • Harris J.E.
        • Huggins R.H.
        • et al.
        International Initiative for Outcomes (INFO) for vitiligo: workshops with patients with vitiligo on repigmentation.
        Br J Dermatol. 2019; 180: 574-579
        • Ezzedine K.
        • Whitton M.
        • Pinart M.
        Interventions for vitiligo.
        JAMA 316. 2016; : 1708-1709
        • Ezzedine K.
        • Eleftheriadou V.
        • Whitton M.
        • Geel N van
        Vitiligo.
        Lancet. 2015; 386: 74-84
        • Grimes P.E.
        • Morris R.
        • Avaniss-Aghajani E.
        • Soriano T.
        • Meraz M.
        • Metzger A.
        Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines.
        J Am Acad Dermatol. 2004; 51: 52-61
        • Hamzavi I.
        • Jain H.
        • McLean D.
        • Shapiro J.
        • Zeng H.
        • Lui H.
        Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the vitiligo area scoring index.
        Arch Dermatol. 2004; 140: 677-683
        • Jung H.
        • Chung H.
        • Chang S.E.
        • Kang D.H.
        • Oh E.S.
        FK506 regulates pigmentation by maturing the melanosome and facilitating their transfer to keratinocytes.
        Pigment Cell Melanoma Res. 2016; 29: 199-209
        • Lan C.C.
        • Chen G.S.
        • Chiou M.H.
        • Wu C.S.
        • Chang C.H.
        • Yu H.S.
        FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo.
        Br J Dermatol. 2005; 153: 498-505
        • Lee J.H.
        • Kwon H.S.
        • Jung H.M.
        • Lee H.
        • Kim G.M.
        • Yim H.W.
        • et al.
        Treatment outcomes of topical calcineurin inhibitor therapy for patients with vitiligo: a systematic review and meta-analysis.
        JAMA Dermatol. 2019; 155: 929-938
        • Nicolaidou E.
        • Antoniou C.
        • Stratigos A.J.
        • Stefanaki C.
        • Katsambas A.D.
        Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy.
        J Am Acad Dermatol. 2007; 56: 274-278
        • Richmond J.M.
        • Strassner J.P.
        • Rashighi M.
        • Agarwal P.
        • Garg M.
        • Essien K.I.
        • et al.
        Resident memory and recirculating memory T cells cooperate to maintain disease in a mouse model of vitiligo.
        J Invest Dermatol. 2019; 139: 769-778
        • Rosmarin D.
        • Pandya A.G.
        • Lebwohl M.
        • Grimes P.
        • Hamzavi I.
        • Gottlieb A.B.
        • et al.
        Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial.
        Lancet. 2020; 396: 110-120
        • Salzes C.
        • Abadie S.
        • Seneschal J.
        • Whitton M.
        • Meurant J.M.
        • Jouary T.
        • et al.
        The Vitiligo Impact Patient Scale (VIPs): development and validation of a vitiligo burden assessment tool.
        J Invest Dermatol. 2016; 136: 52-58
        • Taieb A.
        • Alomar A.
        • Böhm M.
        • Dell’anna M.L.
        • De Pase A.
        • Eleftheriadou V.
        • et al.
        Guidelines for the management of vitiligo: the European Dermatology Forum consensus.
        Br J Dermatol. 2013; 168: 5-19
        • Thomas K.S.
        • Batchelor J.M.
        • Akram P.
        • Chalmers J.R.
        • Haines R.H.
        • Meakin G.D.
        • et al.
        Randomised controlled trial of topical corticosteroid and home-based narrowband UVB for active and limited vitiligo - results of the HI-Light Vitiligo Trial [e-pub ahead of print].
        Br J Dermatol. 2020; (accessed 16 October 2020)https://doi.org/10.1111/bjd.19592
        • Tsuda K.
        • Yamanaka K.
        • Kitagawa H.
        • Akeda T.
        • Naka M.
        • Niwa K.
        • et al.
        Calcineurin inhibitors suppress cytokine production from memory T cells and differentiation of naïve T cells into cytokine-producing mature T cells.
        PLoS One. 2012; 7: e31465
        • van Geel N.
        • Vandendriessche D.
        • Vandersichel E.
        • De Schepper S.
        • Grine L.
        • Mertens L.
        • et al.
        Reference method for digital surface measurement of target lesions in vitiligo: a comparative analysis.
        Br J Dermatol. 2019; 180: 1198-1205